Johnson & Johnson
The Latest
-
Johnson & Johnson Agrees to $6.5 Billion Settlement in Talc Ovarian Cancer Lawsuits
Johnson & Johnson has announced a comprehensive settlement, agreeing to pay $6.5 billion to resolve the vast majority of U.S. lawsuits alleging that its talc-based products caused ovarian cancer. This settlement, facilitated through the third bankruptcy filing of its subsidiary LTL Management, marks a significant development in a series of legal battles that have tarnished the pharmaceutical giant's reputation and impacted its financial performance. 
Johnson & Johnson has announced a comprehensive settlement, agreeing to pay $6.5 billion to resolve the vast majority of U.S. lawsuits alleging that its talc-based products caused ovarian cancer. This settlement, facilitated through the third bankruptcy filing of its subsidiary LTL Management, marks a significant development in a series of legal battles that have tarnished the pharmaceutical giant's reputation and impacted its financial performance. -
Johnson & Johnson's Q1 Results: Medical Device Sales Surge, but Stelara and Vision Products Lag
Johnson & Johnson reported mixed first-quarter results on Tuesday, with adjusted earnings surpassing Wall Street's expectations despite underwhelming sales in its medical devices and pharmaceutical divisions. The healthcare giant's shares closed more than 1% lower following the announcement, as investors weighed the company's performance and ongoing talc-related liabilities. 
Johnson & Johnson reported mixed first-quarter results on Tuesday, with adjusted earnings surpassing Wall Street's expectations despite underwhelming sales in its medical devices and pharmaceutical divisions. The healthcare giant's shares closed more than 1% lower following the announcement, as investors weighed the company's performance and ongoing talc-related liabilities. -
Johnson & Johnson Boosts Cardiac Portfolio with $13.1 Billion Shockwave Medical Acquisition
Johnson & Johnson (J&J), a leading healthcare conglomerate, recently announced a significant expansion of its medical device portfolio with the acquisition of Shockwave Medical for an impressive sum of $13.1 billion. 
Johnson & Johnson (J&J), a leading healthcare conglomerate, recently announced a significant expansion of its medical device portfolio with the acquisition of Shockwave Medical for an impressive sum of $13.1 billion. -
J&J Agrees to $700 Million Settlement Over Talc Safety Investigations
Johnson & Johnson, the pharmaceutical and consumer goods giant, has tentatively agreed to pay approximately $700 million to resolve investigations by 42 U.S. states and Washington, D.C. The probes in question centered on allegations that the company misled consumers regarding the safety of its talc-based products. 
Johnson & Johnson, the pharmaceutical and consumer goods giant, has tentatively agreed to pay approximately $700 million to resolve investigations by 42 U.S. states and Washington, D.C. The probes in question centered on allegations that the company misled consumers regarding the safety of its talc-based products. -
Kenvue, J&J's Consumer-health Spinoff, Soars 20% on First Day of Trading in Largest US IPO Since 2021
The largest US IPO in a year and a half arrived Thursday, May 4, as Johnson & Johnson's wholly-owned consumer health subsidiary Kenvue went public in the United States. Kenvue's shares opened at $25.53 and continued to rise, reaching an intraday high of $26.40, up 20% at one point. 
The largest US IPO in a year and a half arrived Thursday, May 4, as Johnson & Johnson's wholly-owned consumer health subsidiary Kenvue went public in the United States. Kenvue's shares opened at $25.53 and continued to rise, reaching an intraday high of $26.40, up 20% at one point. -
Johnson & Johnson To Permanently Pull Out Talc-Based Baby Powder Worldwide
Johnson's Baby Powder has served as a representation of the business's family-friendly image since 1894. 
Johnson's Baby Powder has served as a representation of the business's family-friendly image since 1894. -
Woman Dies From Rare Johnson & Johnson COVID-19 Vaccine Complication
The woman was diagnosed to have died of thrombosis with thrombocytopenia syndrome (TTS). 
The woman was diagnosed to have died of thrombosis with thrombocytopenia syndrome (TTS). -
Johnson & Johnson HIV Vaccine Fails To Lower Infection
Today, almost 39 million people worldwide have HIV. 
Today, almost 39 million people worldwide have HIV. -
Johnson & Johnson CEO To Step Down, New CEO Named
Alex Gorsky will step down as the company's CEO and be replaced by Joaquin Duato on Jan. 3, 2022. 
Alex Gorsky will step down as the company's CEO and be replaced by Joaquin Duato on Jan. 3, 2022. -
Orlando Mom Tests Positive Despite Getting Johnson & Johnson Vaccine Shot
The study said a single dose of Johnson & Johnson's vaccine was ineffective against new variants. 
The study said a single dose of Johnson & Johnson's vaccine was ineffective against new variants.
